bioAffinity Technologies (BIAFW) Stock: Why It Rose
Updated Oct 23, 7:06 AM ET · latest trade in feed Oct 22, 4:00 PM ET (Finnhub)
Updated Oct 22, 2026, 4:00 PM ET · closing price
- Latest 8-K (Oct 15, 2026): other material events (SEC)
- Latest (Nasdaq last sale, Oct 23, 7:06 AM ET): $0.42, +$0.10 (+33.05%).
- Earnings: latest quarter in SEC XBRL filings (ended Jun 30, 2026): diluted EPS $-0.64; revenue $1.5M, +19% year over year. Sources: SEC EDGAR XBRL.
Sector peers moving today (Business & Consumer Services):CNXC +13.77%ALLE +11.02%TH -10.97%R +10.49%CRAI +9.59%
- Closed at $0.42, +33.05% vs the prior close of $0.31.
- Volume 201 shares, 3.8x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Iqvia (IQV)Charles River Laboratories International (CRL)Medpace (MEDP)Incyte (INCY)ICON (ICLR)Absci (ABSI)
BIAFW jumps 33.0% to $0.42 on 3.8x normal volume. Closed at $0.42, +33.05% vs the prior close of $0.31. Day range $0.42–$0.42, opened at $0.47.
Why Did BIAFW Stock Move Today?
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Last 5 sessions at a glance, then today's full note.
| Session | Close | Change | Volume vs 50-day avg | What the data shows |
|---|---|---|---|---|
| Oct 22, 2026 | $0.42 | +33.05% | — | BIAFW jumps 33.0% to $0.42 on 3.8x normal volume |
Oct 22, 2026 — BIAFW jumps 33.0% to $0.42 on 3.8x normal volume
- Closed at $0.42, +33.05% vs the prior close of $0.31. Day range $0.42–$0.42, opened at $0.47.
- Volume was 201 shares, 3.8x its 50-day average of 53 — unusually heavy trading.
- 52-week range $0.31–$0.56; today's close sits at 42% of that range, 25.2% below the 52-week high.
Data-Driven Bull Case vs. Bear Case + Sector Peer Comparison Table
Points below restate what SEC filings and price data show. They are facts, not a recommendation.
- Share count down 71.5% in a year (buybacks).
- Annual revenue fell 34.2% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: loss of $14.91M.
- High volatility: average daily move of 33.0% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
Sector peers · Services-Commercial Physical & Biological Research
| Ticker | Company | Last price | Day | Below 52w high | Avg $ volume (20d) |
|---|---|---|---|---|---|
| BIAFW | bioAffinity Technologies | $0.42 | +33.05% | 25.2% | $50 |
| IQV | Iqvia | $278.32 | +0.61% | 1.6% | $351.96M |
| CRL | Charles River Laboratories International | $339.66 | -1.51% | 3.3% | $339.57M |
| MEDP | Medpace | $653.96 | -1.29% | 4.5% | $208.55M |
| INCY | Incyte | $116.93 | +3.08% | 11.8% | $200.83M |
| ICLR | ICON | $185.43 | +0.10% | 9.1% | $153.64M |
| ABSI | Absci | $9.37 | -6.67% | 22.3% | $38.72M |
| OABI | OmniAb | $4.78 | -2.75% | 12.0% | $6.52M |
| NRC | Nrc Health | $21.38 | +5.27% | 9.7% | $1.89M |
BIAFW Earnings Date & EPS History
Diluted EPS by fiscal quarter, from bioAffinity Technologies's 10-Q/10-K filings (SEC XBRL).
| Quarter ended | Diluted EPS |
|---|---|
| Jun 30, 2026 | $-0.64 |
| Mar 31, 2026 | $-0.81 |
| Sep 30, 2025 | $-4.74 |
| Jun 30, 2025 | $-5.07 |
| Mar 31, 2025 | $-4.80 |
| Sep 30, 2024 | $-4.84 |
| Jun 30, 2024 | $-0.19 |
| Mar 31, 2024 | $-0.20 |
BIAFW Revenue, Net Income, Cash & Debt
- Revenue (quarter ended Jun 30, 2026): $1.51M
- Net income (quarter ended Jun 30, 2026): $-3.37M
- Cash & equivalents (as of Jun 30, 2026): $2.43M
BIAFW 52-Week High & Low
BIAFW's 52-week range is $0.31 to $0.56. At $0.42 it is 25.2% below the 52-week high and 33.0% above the 52-week low.
BIAFW Valuation: P/E, P/S, P/B, Margins & Cash vs Debt
Computed from bioAffinity Technologies's SEC XBRL filings and the latest price. A ratio is left out when its denominator is zero or negative.
| Measure | Value | How it is calculated |
|---|---|---|
| Market value | $3.40M | price $0.42 × 8.10M shares (Aug 3, 2026) |
| P/S | 0.55 | market value ÷ revenue $6.16M (FY to Dec 31, 2025) |
| P/B | 0.90 | market value ÷ shareholders' equity $3.77M (Jun 30, 2026) |
| Operating margin | -171.6% | FY to Dec 31, 2025 |
| Net margin | -242.0% | FY to Dec 31, 2025 |
| Free cash flow | -$9.39M | operating cash flow $-9.33M − capex $60.57K (FY to Dec 31, 2025) |
| Cash & equivalents | $2.43M | Jun 30, 2026 |
BIAFW 5%+ Holders: Schedule 13D / 13G Filings
Filings by investors reporting a stake of 5% or more (13D = active, 13G = passive), newest first, from SEC EDGAR:
- SCHEDULE 13G filed Oct 1, 2025
- SCHEDULE 13G filed May 14, 2025
- SC 13G filed Oct 10, 2023
Latest BIAFW SEC 8-K & 10-Q Filings
Every SEC filing by or about BIAFW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 13, 2026 · Form PRER14A — PRER14A filing
PRER14A filing
Oct 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Oct 9, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 9, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 29, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 8, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade BIAFW
- Last results release: Aug 7, 2026 (8-K Item 2.02). Previous ones: May 8, 2026, Mar 13, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 6, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 33.05% (largest 33.0%). That is a volatile stock.
- Liquidity: about 127 shares (≈$53) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.42 vs a range of $0.31–$0.56 (42% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 15, 2026; 8-K Oct 13, 2026; 8-K Oct 9, 2026.
- Share count: 8.10M shares outstanding (Aug 3, 2026), -71.5% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Services-Commercial Physical & Biological Research.
BIAFW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | 0.47 | 0.42 | 0.42 | 0.42 | 201 |
| Oct 16, 2026 | 0.47 | 0.56 | 0.31 | 0.31 | 53 |
About bioAffinity Technologies
bioAffinity Technologies (BIAFW) is listed on the Nasdaq and classified by the SEC under “Services-Commercial Physical & Biological Research”. Its business address is in SAN ANTONIO, TX. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1712762.
BIAFW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
BIAFW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $6.16M | $-14.91M | -8.66 | $-9.33M |
| Dec 31, 2024 | $9.36M | $-9.04M | -22.50 | $-7.26M |
| Dec 31, 2023 | $2.53M | $-7.94M | -0.91 | $-6.04M |
| Dec 31, 2022 | $4.80K | $-8.15M | -1.81 | $-4.07M |
| Dec 31, 2021 | — | $-6.33M | — | $-2.05M |
Latest balance sheet: total assets $7.62M, total liabilities $3.85M, cash $2.43M (as of Jun 30, 2026).
BIAFW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 7, 2026 | 8-K Item 2.02 (results) | — |
| May 8, 2026 | 8-K Item 2.02 (results) | — |
| Mar 13, 2026 | 8-K Item 2.02 (results) | — |
| Nov 14, 2025 | 8-K Item 2.02 (results) | — |
| Aug 14, 2025 | 8-K Item 2.02 (results) | — |
| May 15, 2025 | 8-K Item 2.02 (results) | — |
| Mar 31, 2025 | 8-K Item 2.02 (results) | — |
| Nov 14, 2024 | 8-K Item 2.02 (results) | — |
| Jul 9, 2024 | 8-K Item 2.02 (results) | — |
| May 16, 2024 | 8-K Item 2.02 (results) | — |
| Apr 1, 2024 | 8-K Item 2.02 (results) | — |
| Mar 5, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Services-Commercial Physical & Biological Research
Iqvia (IQV)Charles River Laboratories International (CRL)Medpace (MEDP)Incyte (INCY)ICON (ICLR)Absci (ABSI)OmniAb (OABI)Nrc Health (NRC)Maxcyte (MXCT)OneMedNet (ONMD)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Space Exploration Technologies (SPCX)Meta Platforms (META)Tesla (TSLA)Apple (AAPL)Sandisk (SNDK)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on BIAFW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 22, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.